2023年5月18日 · The establishment of consensus diagnostic criteria for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), …

2024年4月2日 · Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neuropsychiatric syndrome that can occur in some patients who are treated with …

2025年2月14日 · Immune effector cell-associated neurotoxicity syndrome (ICANS) is a clinical and neuropsychiatric syndrome that can occur in the days to weeks following administration of …

2025年3月13日 · Immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS) are major complications of immune-based cancer therapies, …

For patient with early fever (within 72 hrs) or signiicant comorbidities can consider early tocilizumab. Tocilizumab 8 mg/kg (Consider alternative agents after 2 doses) *No more than 3 …

ICANS is typically associated with CRS, though few patients may develop ICANS without previous or concomitant CRS, ICANS may develop after CRS symptoms have resolved; rarely both …

ICANS may occur concurrently with CRS, shortly after CRS abates, and with delayed onset occurring up to one month after infusion. ICANS is typically self-limited with symptoms most …

2025年2月15日 · CRS and ICANS are significant toxicities in CAR T-cell therapy, with refined diagnostic criteria improving management. CRS management involves early intervention with …

2022年2月7日 · ICANS is a common and usually reversible toxicity of CAR-T cell therapy, occurring within a week of infusion, often after cytokine release syndrome. ICANS is a clinical …

Here, we review recent data suggesting a significant proportion of ALL patients are at risk of developing severe, sometimes life-threatening, CRS and ICANS after CD19 and CD22 CAR T …